RRI Responds to Philips Recall
The respiratory equipment notes that its Purify 03 devices are made for cleaning accessory items such as masks and tubing, not the core PAP therapy devices where PE-PUR foam is located.
- By David Kopf
- Jun 24, 2021
Respiratory equipment maker Responsive Respiratory Inc. (RRI) has released a statement regarding its Purify 03 cleaning devices in relation to Philips’ recall of millions of PAP therapy devices and ventilators.
Last week, Philips announced it was recalling millions of bi-level positive airway pressure (Bi-PAP), continuous positive airway pressure (CPAP), and mechanical ventilator devices because PE-PUR foam used in the devices that could degrade and off-gas, causing inflammations or respiratory issues, and possibly become toxic or carcinogenic.
Philips said in statements that the use of unapproved cleaning methods, such as ozone, as well as high heat and high humidity environments could contribute to the foam’s degradation.
RRI noted in a follow-up statement that the Philips recall “does not correlate” to RRI’s Purify O3 devices, which use ozone. RRI emphasized that its devices are used for accessory items and not the core devices, where the PE-PUR foam is located.
“It is important to note that Purify O3 and Purify O3 Elite do not connect directly to, and do not circulate ozone through CPAP/BiPAP machines,” RRI underscored. “Purify O3 and Purify O3 Elite are designed for disinfection and deodorizing purposes of accessory items, including masks, tubing and humidification chambers, and are not indicated or recommended for use with CPAP/BiPAP machines.”
RRI added that, per Philips statement, “the off-gassing and degradation of the PE‐PUR foam may be present from the outset of the use of its products and that humidity and high heat environments may also contribute further to its breakdown.”
More information on Purify 03 products are at www.purifyo3.com/purify‐o3.
About the Author
David Kopf is the Publisher HME Business, DME Pharmacy and Mobility Management magazines. He was Executive Editor of HME Business and DME Pharmacy from 2008 to 2023. Follow him on LinkedIn at linkedin.com/in/dkopf/ and on Twitter at @postacutenews.